At ASDS 2025, Galderma unveiled pivotal new data from its range of pioneering Restylane hyaluronic acid (HA) injectables, highlighting its versatility in improving the chin profile with Restylane Lyft, temple volume with investigational Restylane Contour* and skin quality in the décolletage (neckline) with investigational Restylane Skinboosters*1-3
Nine-month results from a first-of-its-kind clinical trial were presented, reinforcing that the treatment regimen of Restylane Lyft or Restylane Contour with Sculptra delivers sustained aesthetic facial improvements for patients experiencing facial aesthetic changes after medication-driven weight loss4
The company also presented new phase III data on its investigational product Relfydess (RelabotulinumtoxinA)* relating to its rapid onset as early as day one and long duration of effect on frown lines and crow’s feet5

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it presented new data from its Injectable Aesthetics portfolio and pipeline at the American Society for Dermatologic Surgery (ASDS) 2025 Annual Meeting, held in Chicago from November 13-16. Six poster presentations spotlighted the latest data on Restylane, Sculptra, and Relfydess*, while a series of onsite educational events through the Galderma Aesthetic Injector Network (GAIN) further showcased Galderma’s commitment to advancing aesthetic medicine through science-backed solutions. Spanning key treatment areas, the findings reinforce Galderma’s leadership in delivering meaningful outcomes and addressing unmet patient needs through robust clinical evidence and practitioner education.